Professional Documents
Culture Documents
Chapter-3 Synthesis, Characterization of Some Novel Chromeno Oxadiazole Derivatives
Chapter-3 Synthesis, Characterization of Some Novel Chromeno Oxadiazole Derivatives
36
3.1. Introduction
Oxadiazole, a heterocyclic nucleus has attracted a wide attention for the chemist in search for the
new therapeutic molecules. Oxadiazoles and their derivatives are considered as simple five membered
heterocycles possessing one oxygen and two nitrogen atoms. The first synthesis of 1,2,4-oxadiazoles,
initially named furo [ab-1]diazoles, was achieved by Tiemann and Kruger in 1884 [[1a, b,c]. Oxadiazole
exists in different isomeric forms such as 1,2,4-, 1,2,5-, 1,3,4- and 1,2,3-oxadiazole (161 a-d).
Oxadiazole is a very weak base due to the inductive effect of the extra heteroatom. The replacement of
two -CH= groups in furan by two pyridine type nitrogen (-N=) reduces aromaticity of resulting
oxadiazole ring to such an extent that the oxadiazole ring exhibit character of conjugated diene.
N N N N
N N N N
O O O O
a b c d
1,2,4-Oxadiazole 1,2,5-Oxadiazole 1,3,4-Oxadiazole 1,2,3-Oxadiazole
(161 a-d)
Electrophilic substitutions in oxadiazole ring are extremely difficult at the carbon atom because
of the relatively low electron density on the carbon atom which can be attributed to electron withdrawal
effect of the pyridine type nitrogen atom. However the attack of electrophiles occurs at nitrogen, if
oxadiazole ring is substituted with electron-releasing groups. Oxadiazole ring is generally resistant to
important class of natural and synthetic products, many of which exhibit useful biological activities [2].
78
The interest in five-membered systems containing one oxygen and two nitrogen atoms (positions 1, 2,
and 4) stems from the occurrence of saturated and partially saturated 1,2,4-oxadiazoles in biologically
Oxadiazole rings have been introduced into drug discovery programs for several different
purposes. In some cases, they have been used as an essential part of the pharmacophore, favorably
contributing to ligand binding [5]. In other cases, oxadiazole moieties have been shown to act as a flat,
aromatic linker to place substituents in the appropriate orientation [6] as well as modulating molecular
properties by positioning them in the periphery of the molecule [4]. It has also recently been shown that
architecture within the aldose reductase active site by using two structurally related oxadiazole
regioisomers [7]. Also, oxadiazoles have been used as replacements for carbonyl containing compounds
are in late stage clinical trials, including Zibotentan (162) as an anticancer agent [9] and Ataluren (163)
for the treatment of cystic fibrosis [10]. So far, one oxadiazole containing compound, Raltegravir (164)
[11], an antiretroviral drug for the treatment of HIV infection, has been launched onto the marketplace.
It is clear that oxadiazoles are having a large impact on multiple drug discovery programs across a
variety of disease areas, including diabetes, obesity [12], inflammation [13] cancer [14] and infection
[15]. Aside from being biologically active themselves, 1,2,4- oxadiazoles also present an important
linking site, for instance, for terminal amino groups of biologically important molecules. There are
many drugs containing 1,2,4-oxadiazoles also many molecules are under development stages. Few
79
O O
O H O
N N O N OH
S N F O N OH F
N N N
N H H
O N N N
O N
N
O O
162 Zibotentan 163 Ataluren 164 Raltegravir
anticancer agent cystic fibrosis antiretroviral
F F
F O
N O
O N N N N
N N N N
O O O N
O NH NO2
O S
N
N N O
F
165 167
Antiparkinsonic 166
Antiparkinsonic Cannabinoid receptor
N
NH N
N O
N
N
N
O
Palazzo et al, (1961) are the first to report the synthesis and pharmacological screening of 1,2,4-
oxadiazole derivatives. They synthesised a series of 1,2,4-oxadiazole derivatives (170, 171) and studied
their Nonspecific antispasmodic activity in guinea pig intestine oxygenated thyroid liquid. Also the
synthesised compounds were screened for their local anaesthetic action [16].
N
N
N N
O N N
O
170 171
80
Fig 3.3: Nonspecific antispasmodic active oxadiazole derivatives
Later in (1969) Breuer prepared a nitro furan containing oxadiazoles and studied the
N NH2
O2N O O N
172
Johan et al, (1972) have reported the synthesis of bis 1,2,4-oxadiazole derivatives and their
O N N O
N O O N
R N N R N N
R R
173
174
NCS
N R1
R Where R, R1= Alkyl, Phenyl
N O
175
Tully et al, (1991) have reported the synthesis and antagonist properties of 2-
(0xadiazolyl)imidazo[ 1,2-a] pyrimidines (176). These are a class of compounds which bind to
benzodiazepine receptors with moderate to weak affinity, and yet display antianxiety properties of
81
similar potency to chlordiazepoxide in animal models while demonstrating reduced or negligible
R4 N N N O
N N
R3 R5 Where R1, R2, R3. R4, R5 = Cl, Br, Me, Ethyl, -OCH3
1
R 2 R
176
These coumarin derivatives were isolated and characterized, and evaluated for their ability to inhibit
trypsin, glucuronidase, and soybean lipoxygenase. The compounds were also tested for antioxidant
activity, and as antiiflammatory agents in the rat carrageenin paw edema assay. Compound (177) found
O
N N
O O
177
Oxadiazoles containing terminal amino acid moiety (178) was synthesized and studied their
antimicrobial activity by Leite and co-workers (2000). Compounds with leucine, isoleucine or aspartic
acid residues were the most active against different Gram positive and negative bacteria although their
activity was lower than Ciprofloxacin. Interestingly, after intravenous administration, compounds with
phenylalanine, valine, aspartic acid or glutamic acid residues were the most active in inhibiting the rat
82
O
H NH2 Where R= CH3, CH2(CH3)2, CH2CO2H, CH2Ph,
N N
N R CH2CH2CO2H, (CHCH3)2
O O
178
Gezginci et al, (2001) have synthesised 1,2,4-Oxadiazoles (179) isosteres of pyridine- and
pyrazine-carboxylic acids and tested for their anti-mycobacterial activity and found potency from 2 to 8
N
X
O N X = C, CH, N.
N
S O
179
Jager et al, (2002) have reported the ring fission of oxadiazole system to form substituted
guanidines (183) in the presence of base and long reaction times [24].
Cl
N O
Cl Cl N N
N O
Cl NH 182
Cl N
Cl
H2N O
180 181
Cl N N
183
oxadiazole derivatives (184) and studied their preliminary antimicrobial activity against Staphylococcus
aureus, Mycobacterium smegmatis, and Candida albicans, few of the oxadiazole derivatives shown
83
R
N
Where R = CH3, Cl, Ethyl
N O
184
Cottrell and co-workers (2004) synthesized oxadiazole derivatives and evaluated for their
activity against kinetoplastid parasites. Compound (185a) displayed modest selectivity for Leshmania
donovani axenic amastigote-like parasites over J774 macrophages, PC3 prostate cancer cells, and Vero
cells (6.4-fold, 3.8-fold, and 9.1-fold, respectively). In a murine model of visceral leishmaniasis,
compound (185a) decreased liver parasitemia caused by Leshmania donovani by 48% when given in
five daily i.v. doses at 5 mg/kg and by 61% when administered orally for 5 days at 50 mg/kg, while
compound (185b) showed 30-fold selectivity against Vero cells but was not selective against PC3 cells
[26].
N O SCN
N O SCN
N
N
Cl
Br
185a
185b
The IL-8 receptor is a seven trans membrane domain G-protein coupled receptor (GPCR) that is
found in abundant quantities on neutrophils. Inhibition of the actions of IL-8 on neutrophils should limit
their migration to the sites of inflammation, prevent activation, and thus inhibit the subsequent release
of lysosomal enzymes. Wells et al, (2004) synthesized oxdiazole derivative (186) as interleukin-8 (IL-8)
antagonists these compounds exhibit activity in an IL-8 binding assay as well as in a functional assay of
84
Cl
N O
N O N N
186
The common approach used in diabetes treatment is the inhibition of the dipeptidyl peptidase IV
enzyme (DPP-IV). Xu et al, (2005) have synthesized a novel amino acid pyrrolidide analogs as DPP-IV
inhibitors, the introduction of the polar acidic heterocycle 5-oxo-1,2,4-oxadiazole at the 3rd position of
the terminal phenyl group of compound (187) improved both potency and selectivity [28].
H
N
O O
O N N
TFA NH2
187 F
Sun et al, (2006) synthesized 1,2,4-oxadiazoles (188a-b) as human tryptase inhibitors for
evaluation as a new class of anti-asthematic agent. The inhibitor design is focused on using a prime-side
hydrophobic pocket and the S2 pocket of β-tryptase to achieve inhibition potency and selectivity over
85
O
H
N N
O
R O N O a: R = -CH2Ph
b: R = -CH2Me
NH
NH2
O
188a-b
Boys et al, (2006) reported a series of β-substituted 1,2,4-oxadiazolyl butanoic acids (189a-c) as
R
H
N N N
CO2H a: R = H,
N O b: R = Me,
c: R = Ph,
189 a-c
Koufaki et al, (2007) have synthesised a series of 1,2- dithiolane-3-pentanoic acid (a-lipoic acid)
and its derivatives and evaluated their neuroprotective activity. This study showed that it is possible to
obtain strong neuroprotective compounds by inserting a heterocyclic ring, whose nature has a strong
effect on the activity, in the alkyl- 1,2-dithiolane moiety in conjunction with another antioxidant entity
such as a free or protected catechol moiety. Compound (190) containing the 1,2,4-oxadiazole linker as
amide bioisostere, was among the most potent in the series [31].
OR
OR
S S N Where R = H, CH3
N
O
190
86
Fig 3.17: 1,2- Dithiolane-3-pentanoic acid oxadiazole derivatives
Sirtuins are a class of seven proteins (SIRT1–7) which play a major role in age-related diseases.
have been synthesized and tested for their SIRT1 and SIRT2 activity by Huhtiniemi et al, (2008).
Compound (191) was the most potent SIRT1 inhibitor in the series [32].
CF3
O
NH
N HN NH
N O
O
191
(trifluoromethyl)phenyl)semicarbazide
Koryakova et al, (2008) reported the synthesis and biological evaluation of heteroaryl substituted
kinase. They found out that the inhibitory activity of the synthesized compounds is highly dependent on
the character of substituents in the phenyl ring and the nature of terminal heterocyclic fragment of the
core molecular scaffold. The most potent compounds from this series contain 3,4-di-methyl (192a) or 2-
metoxy substituents (192b) within the phenyl ring and 3-pyridine fragment connected to the 1,2,4-
oxadiazole heterocycle. These compounds selectively inhibit GSK-3β kinase with IC50 value of 0.35 and
R2
3
R R1 N
a: R1 = H, R2 = Me, R3 = Me
N N
H N b: R1 = 2-OMe, R2 = H, R3 = H.
N N
O
O
192a-b
87
Fig 3.19: N-[3-(4-Phenylpiperazin-1-yl)propyl]-1,2,4-oxadiazole-5-carboxamide derivatives
Rakesh et al, (2009) have developed and studied series of oxadiazole derivatives throughout the
course of development of anti-tuberculosis drugs, substitution of the benzyl-piperazine ring of the lead
compound with a 5-phenyl-1,2,4-oxadiazol-3-yl moiety lead to compound (193) with improved activity
[34].
N O N
O
O
N
O
193
containing 2-fluoro-4-methoxy moiety and their antibacterial and antifungal studies. Few oxadiazole
derivatives compounds showed significant antibacterial activity against Escherichia coli and
Br
F N N F
F N N
O O
O
O
194 O
195
Novel nitrocatechol-substituted heterocycles were designed and evaluated by Kiss and co-
workers (2010) for their ability to inhibit catechol-O-methyltransferase (COMT). They found that
replacement of the pyrazole core of the initial hit (196) with a 1,2,4-oxadiazole ring resulted in a series
of compounds endowed with longer duration of COMT inhibition. Incorporation of a pyridine N-oxide
residue at position 3 of the 1,2,4-oxadiazole ring led to analogue (197) which was found to possess
88
activity comparable to entacapone and lower toxicity in comparison to Tolcapone. Lead structure (197)
was systematically modified in order to improve selectivity and duration of COMT inhibition as well as
peripheral inhibitor, which was taken for clinical evaluation as an adjunct to L-Dopa therapy of
Cl NO2 NO2
HO HO
HO
O O
HO HO N
N
HO N N
HO N N
H Cl
Cl
N N
O O
196 198
197
Hencken et al, (2010) have reported the oxadiazole derivatives (199) of Dehydroartemisinin
(DART) and its in vitro activity in the toxoplasma cycle. Few of the 1,2,4-oxadiazole derivatives shown
less toxicity and 100 times more inhibitory activity than the frontline drug Trimethoprim [37].
H
O
O
O
H
O Where R= Me, Ph
N O
N
R
199
89
Demont et al, (2011) reported the discovery of new SIP1 agonist compound (200) which
contains 1,2,4-oxadiazole ring in the moiety. This compound found to be more efficacious and shows
NC
O N
O
N
N
O Na
O
200
dihydroisoquinolin-2(1H)-yl)propanoate
synthesized and their antibacterial activity was evaluated by Kumar et al, (2011). Few of the molecules
containing oxadiazole ring shown antibacterial activities comparable to the parent compound against all
F O
O
R1 Where R1= H, CH3
Ar O
N
N OH R2 = Ethyl, Cyclopropyl
N
N N R3
2
R3= H, -OCH3
R
201
The Wnt signaling pathway (is a network of proteins that passes signals from receptors on the
surface of the cell to DNA expression in the nucleus. It controls cell-cell communication in the embryo
and adult) is crucial to the regulation of key cellular process. When deregulated it has been shown to
play important role in the growth and progression of multiple human cancers. Shultz et al, (2012) have
90
oxadiazole derivatives (202) by biophysical, computational characterisation, structural activity
N N R3
1
N
R S
N
O N R4
Where R1 =Ph. Py, Furan, Thiophene
202
R2, R3, R4 = H, -OMe, Me, F,
R2
Diacetyglycerol acyltransferate, DGAT1 is a promising target enzyme for obesity due to its involvement
in the committed step of triglyceride biosynthesis. Jadhav and co-workers (2012) introduced 1,2,4-
oxadiazole ring in the existing drug (203) to increase the solubility of the compound without affecting
O OH
N
H O O
O
N
N N
H OH
N
O O
F N
S H R N
N H
203 H
204
discussed in detail in Chapter-II. As evident from the above discussions the inclusion of two bioactive
motifs like benzopyran and oxadiazole into a single carbon skeleton gives new class of molecules. Also
combination of chromene and oxadiazoles may further enhance the biological activity. Keeping in view
91
of the biological importance of 1,2,4-oxadiazoles, we synthesized a novel series of 1,2,4-oxadiazoles
The general strategy used for the synthesis of 210 (a-n), (1,2,4-oxadiazol-3-yl)-3,4-dihydro-2H-
chromen-2-amine is outlined in Scheme-3.2. Compound (207) was prepared by following the reported
procedure [42]. Subsequent reduction of (207) using sodium borohydride in alcohol medium gave
compound (208) in high yield. A Variety of methods are present for the synthesis of various
amidoximes like action of hydroxylamine on nitriles. This is the most used process for the preparation
liberating hydroxylamine from its hydrochloride using sodium carbonate, adding an equivalent amount
of nitrile and enough alcohol to obtain a clear solution, and keeping the mixture at 60-80°C for few
hours [1a, b, c]. Amidoxime (209) was prepared by treating compound (208) with hydroxylamine
hydrochloride in the presence of base. Further 1,2,4-oxadiazole derivatives were prepared by treating
amidoxime (209) with different aldehydes in microwave condition for 5 min [43, 44, 45].
92
Ethanol
CHO Triethylamine CN NaBH4/MeOH CN
CN
CN Refux, 2hr O NH2
OH O NH
205 206 207 208
OH
N
NH2OH/MeOH NH2 Where R=
a: 2-Chlorophenyl
Refux, 12hr O NH2 b: 4-Chlorophenyl
209 c: 2-Hydroxyphenyl
d: 3,4-Dimethoxyphenyl
e: 4-Fluorophenyl
R-CHO Microwave f: Cinnamyl
g: 3-Nitrophenyl
h: 5-Bromo-2-fluorophenyl
i: Phenyl
N O j: 2-Thiophenyl
R k: 4-Hydroxy-3-methoxyphenyl
N
l: 4-Bromophenyl
O N m: 2-Thiozolyl
n: 4-Fluoro-3-phenoxy phenyl
(210 a-n) R
OH O
N OH N
N R
NH2 -H2O N
CHO N R H
R
O NH2 O N
O N
R R
O
N
R
N
O N
The structure of (210a) was confirmed based on the elemental analyses and spectral studies. The
efficiency of the first reaction prompted us to extend this procedure to synthesize series of compounds
93
Melting points were determined by open capillary method and were uncorrected. The IR spectra
(In KBr pellets) were recorded on a Shimadzu FT-IR 157 spectrophotometer. 1H -NMR spectra were
recorded on a Perkin-Elmer EM 300MHz spectrometer using TMS as internal standard. The mass
spectra were recorded on a JEOL JMS-D 300 spectrometer operating at 70 eV. Purity of the compounds
olefinic proton. Peaks which appeared at δ 7.16-7.67 were assigned to aromatic protons. A singlet peak
at δ 8.83 is observed due to –NH proton. In IR Spectrum peaks at 3293 cm-1, 2231 cm-1 represents the
presence of –NH and CN functional groups respectively. Finally, the observance of M+ peak at m/z 171
to amidoxime at δ 5.9 and δ 9.66 assigned to NH and OH respectively in the 1H NMR spectrum. Peaks
which appeared at δ 7.17-7.67 were assigned to aromatic protons. In IR spectrum two peaks at 3416 cm-
1
and 3386 cm-1 are indicative of –OH and –NH groups. Finally, the observance of M+ peak at m/z 208
recording their IR, 1H NMR and mass spectra. IR spectrum of oxadiazole (210a) showed absorption at
3006 cm-1 which is due to the aromatic stretching. An absorption band at 1599 cm-1 is due to the C=N
group, band at 1057 cm-1 is due to stretching of oxadiazole. The 1H NMR spectrum of (210a) showed
multiplet in the region of δ, 7.03- 7.14, δ 7.5 is due to aromatic proton. The mass spectrum of (210a)
showed molecular ion peak at m/z 450 & 452 which is in agreement with the molecular formula
C24H17Cl2N3O2. Similarly the spectral values for all the compounds and C, H, N analyses are given in
94
3.3. Synthesis
To a stirred solution of salicylaldehyde (205) (10g, 0.08 mol) and malononitrile (206) (5.41g,
0.081 mol) in ethanol (150 ml) was added triethylamine (1 ml, 0.0081 mol).The resulting mixture was
refluxed for 30 min and the completion of reaction was confirmed by TLC. Reaction mixture was then
allowed to cool to room temperature. The precipitate formed was isolated by filtration and washed with
ethanol to get pure product as yellow solid and was recrystalised from ethanol.
ml) was added sodium borohydride (0.83g, 0.034 mol) at 0oC. Reaction mixture was stirred for 20
minutes. The completion of reaction was confirmed by TLC. Reaction mixture poured to water,
precipitated solid was filtered, washed with water and dried to get pure product.
methanol (100 ml) was added hydroxylamine hydrochloride (7.8g, 0.1 mol) and triethylamine (6.9g,
0.06 mol) at 0oC. Reaction mixture was heated to reflux for 8 hours; TLC confirmed the completion of
reaction. Reaction mixture was cooled to room temperature, diluted with water (100 ml), solid separated
mmol) was irradiated in microwave synthesis system at 120W power and 100 ºC temperature for 5
95
minutes. The completion of reaction was monitored by TLC. The reaction mixture was diluted with
diethyl ether to get desired compound as a solid, which was recrystalised using ethanol.
3.4. Characterization
Yield 90 %, Yellow solid, IR (KBr, νmax cm-1): 3293 (NH), 2231 (CN), 1653 (CH), 1256 (C-O).
1
H NMR (300 MHz, DMSO-d6) δ (ppm): 5.84 (1H, s, CH=C); 7.18–7.21 (1H, m, Ar-H); 7.24–7.29 (1H,
m, Ar-H); 7.55–7.61 (2H, m, Ar-H); 8.83 (1H, s NH). MS: m/z = 171 (M+). Anal. calcd. for C10H6N2O:
Yield 88 %, Yellow solid, IR (KBr, νmax cm-1): 3360 (NH), 3041 (CH), 1606 (C=N), 1254 (C-
O). 1H NMR (300 MHz, DMSO-d6) δ (ppm): 2.5 (m, 2H, CH2), 2.6 (bs, 2H, NH2), 3.5 (m, 1H, CH), 4.8
(m, 1H, CH), 7.18-7.21 (m, 1H, Ar-H), 7.24-7.29 (m, 1H, Ar-H), 7.55-7.61 (m, 2H, Ar-H). MS: m/z =
200.2 (M+). Anal. calcd. for C11H9N3O: C, 66.32; H, 4.55; N, 21.09. Found: C, 66.43; H, 6.48; N,
21.06%.
Yield, 96 %, Off white solid, M.p. 187-190 oC, IR (KBr, νmax cm-1): 3416 (O-H), 3386 (N-H),
3003 (C-H), 1699 (C=N), 1284 (C-O). 1H-NMR (300 MHz, DMSO-d6) δ (ppm): 2.5 (m, 2H, CH2), 3.5
(m, 1H, CH), 4.18 (m, 1H, CH), 5.9 (bs, 2H, NH2), 7.18–7.21 (m, 1H, Ar-H), 7.24–7.29 (m, 1H, Ar-H),
7.55–7.61 (m, 2H, Ar-H), 9.63(s, 2H, NH2). MS: m/z =208.1 (M+1). Anal. calcd. for C10H13N3O2: C,
96
3.4.1.4. N-(2-Chlorobenzylidene)-3-(5-(2-chlorophenyl)-1,2,4-oxadiazol-3-yl)-3,4-dihydro-2H-
chromen-2-amine (210a)
Yield 85 %, Off white solid, M.p. 150-152 oC, IR (KBr, νmax cm-1): 3006 (C-H), 1699 (C=N),
1284 (C-O). 1H NMR (300 MHz, DMSO-d6) δ (ppm): 2.59 (m, 2H, CH2), 3.3 (m, 1H, CH), 3.88 (m,
1H, CH), 6.31 (d, 1H, Ar-H, J = 8 Hz), 6.76-6.80 (m, 1H, Ar-H), 6.88 (d, 1H, Ar-H, J = 8 Hz), 6.96 (m,
1H, Ar-H), 7.03-7.14 (m, 3H, Ar-H), 7.15 (m, 2H, Ar-H), 7.34-7.29 (m, 1H, Ar-H), 7.58-7.61 (m, 2H,
13
Ar-H), 8.97 (s, 1H, CH). C NMR (75 MHz, DMSO-d6) δ (ppm): 176.2, 173.2, 159.5, 155.6, 141.3,
137.8, 135.0, 134.8, 133.5, 131.2, 129.4, 129.1, 128.8, 128.4, 127.5, 126.7, 124.5, 120.5, 98.2, 47.4,
28.3. MS: m/z = 450 (M+1), 452 (M+2). Anal. calcd. for C24H17Cl2N3O2: C, 64.01; H, 3.81; N, 9.33.
3.4.1.5. N-(4-Chlorobenzylidene)-3-(5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl)-3,4-dihydro-2H-
chromen-2-amine (210b)
Yield 88 %, Light brown solid, M.p. 145-147 oC, IR (KBr, νmax cm-1): 3013 (C-H), 1689 (C=N),
1413 (C=C), 1284 (C-O). 1H NMR (300 MHz, DMSO-d6) δ (ppm): 2.58 (m, 2H, CH2), 3.3 (m, 1H,
CH), 3.94 (m, 1H, CH), 6.69 (m, 1H, Ar-H), 6.91 (d, 1H, Ar-H, J = 7.6 Hz), 7.0 (t, 1H, Ar-H, J = 7.6
Hz), 7.19 (d, 1H, Ar-H, J = 7.6 Hz), 7.47-7.50 (m, 4H, Ar-H), 7.8 (d, 2H, Ar-H, J = 8.4 Hz), 7.90 (d,
2H, Ar-H, J = 9.2 Hz), 8.97 (s, 1H, CH). 13C NMR (75 MHz, DMSO-d6) δ (ppm): 192.1, 168.3, 166.6,
165.3, 162.4, 160.8, 135.4, 132.5, 131.9, 129.9, 127.9, 125.0, 120.2, 120.0, 119.6, 119.2, 117.3, 115.3,
105.8, 96.2, 47.0.4, 21.3. MS: m/z = 450 (M+1), 452 (M+2). Anal. calcd. for C24H17Cl2N3O2: C, 64.01;
2H-chromen-2-amine (210c)
97
Yield 90 %, Off white solid, M.p:130-132 oC, IR (KBr, νmax cm-1): 3387 (O-H), 2992 (C-H),
1597 (C=N), 1495 (C=C), 1366 (C-N), 1271 (C-O). 1H NMR (300 MHz, DMSO-d6) δ (ppm): 2.90 (m,
1H, CH2), 3.07 (m, 2H, CH2), 3.90 (m, 1H, CH), 6.73 (t, 1H, Ar-H, J = 7.6 Hz), 6.80 (d, 1H, Ar-H, J = 8
Hz), 6.96-7.05 (m, 5H, Ar-H), 7.15 (d, 1H, Ar-H, J = 7.8 Hz), 7.44-7.53 (m, 2H, Ar-H), 7.54-7.55 (m,
1H, Ar-H), 7.60-7.62 (m, 1H, Ar-H), 9.0 (s, 1H, CH), 9.07 (bs, 1H, -OH). 13C NMR (75 MHz, DMSO-
d6) δ (ppm): 173.2, 166, 161, 160, 136.2, 134.8, 130.8, 130.7, 129.2, 128.9, 128.3, 125.0, 1119.2, 115.2,
107.2, 98.2, 48.0.4, 28.3. MS: m/z = 414.1 (M+1). Anal. calcd. for C24H19N3O4: C, 69.72; H, 4.63; N,
oxadiazol-3-yl)-2H-chromen-2-amine (210d)
Yield 93 %, Off white solid, M.p. 141-143 oC, IR (KBr, νmax cm-1): 3012 (C-H), 1658 (C=N),
1440 (C=C), 1346 (C-N), 1293 (C-O). 1H NMR (300 MHz, DMSO-d6) δ (ppm): 2.59 (m, 1H, CH2),
2.79 (m, 1H, CH2), 3.5 (m, 1H, CH), 3.84 (s, 6H, 2-OCH3), 3.94 (s, 6H, 2-OCH3) 4.09 (m, 1H, CH),
13
6.65-6.75 (m, 3H, Ar-H), 6.98-7.11 (m, 4H, Ar-H), 7.47-7.56 (m, 3H, Ar-H), 9.02 (s, 1H, CH). C
NMR (75 MHz, DMSO-d6) δ (ppm): 176.1, 172.7, 161.8, 156.2, 154.5, 153.8, 153.5, 153.1, 133.8,
131.0, 128.2, 126.3, 124.1, 122.0, 121.5, 121.8, 120.8, 118.2,117.8,116.2,115.3, 97.1, 57.3, 47.8, 27.3.
MS: m/z = 502.2 (M+1). Anal. calcd. for C28H27N3O6: C, 67.05; H, 5.43; N, 8.38. Found: C, 67.12; H,
5.38; N, 8.38.
3.3.1.8 N-(4-Fluorobenzylidene)-3-(5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl)-3,4-dihydro-2H-
chromen-2-amine (210e)
Yield 93 %, Off white solid, M.p. 154-157 oC, IR (KBr, νmax cm-1): 3010 (C-H), 1654 (C=N),
1432 (C=C), 1340 (C-F), 1284 (C-O). 1H NMR (300 MHz, DMSO-d6) δ (ppm): 2.58 (m, 2H, CH2), 3.3
98
(m, 1H, CH), 3.88 (m, 1H, CH), 6.69 (m, 1H, Ar-H), 6.91 (d, 1H, Ar-H, J = 7.6 Hz), 7.0 (t, 1H, Ar-H, J
13
= 7.6 Hz), 7.19-7.29 (m, 5H, Ar-H), 7.47-7.50 (m, 4H, Ar-H), 8.97 (s, 1H, CH). C NMR (75 MHz,
DMSO-d6) δ (ppm): 175.9,172.8, 166.2, 162.9, 161.4, 156.6, 136.5, 131.1, 130.2, 129.3, 128.0, 126.7,
122,6, 117.3, 116.0, 115.5, 97.6, 47.7, 27.9. MS: m/z = 418 (M+1). Anal. calcd. for C24H17F2N3O2: C,
amine (210f)
Yield 78 %, Brown solid, M.p.160-162 oC, IR (KBr, νmax cm-1): 2996 (C-H), 1656 (C=N), 1478
(C=C), 1352 (C-N), 1281 (C-O). 1H NMR (300 MHz, DMSO-d6) δ (ppm): 2.88 (m, 1H, CH2), 3.01 (m,
1H, CH2), 3.68 (m, 1H, CH), 4.12 (m, 1H, CH), 5.8 (m, 1H, CH), 6.70 (m, 2H, Ar-H, CH), 6.84-6.99
(m, 3H, Ar-H,CH), 7.15-7.30 (m, 10H, Ar-H), 8.5 (s, 1H, CH). 13C NMR (75 MHz, DMSO-d6) δ (ppm):
166.9, 166.0, 166.1, 162.8, 161.3, 156.1, 136.4, 131.0, 130.1, 130.5, 129.3, 128.0, 126.4, 124.3, 122,5,
117.1, 116.1, 115.4, 97.5, 47.1, 27.2. MS: m/z = 434.2 (M+1). Anal. calcd. for C28H23N3O2: C, 77.58;
chromen-2-amine (210g)
Yield 87 %, Yellow solid, M.p. 168-170 oC, IR (KBr, νmax cm-1): 3012 (C-H), 1648 (C=N),
1537(N-O), 1358(N-O), 1490 (C=C), 1330 (C-N), 1274 (C-O). 1H NMR (300 MHz, DMSO-d6) δ
(ppm): 2.60 (m, 1H, CH2), 3.17 (m, 1H, CH2), 3.58 (m, 1H, CH), 4.06 (m, 1H, CH), 6.76 (t, 1H, Ar-H,
J = 7.6 Hz), 6.85 (d, 1H, Ar-H, J = 8 Hz), 6.96-7.25 (m, 5H, Ar-H), 7.35 (d, 1H, Ar-H, J = 7.8 Hz),
7.44-7.53 (m, 2H, Ar-H), 7.54-7.55 (m, 1H, Ar-H), 7.60-7.62 (m, 1H, Ar-H), 9.1 (s, 1H, CH). 13C NMR
(75 MHz, DMSO-d6) δ (ppm):175.1,172.2, 166.4, 163.0, 161.1, 155.6, 131.5, 131.1, 130.2, 129.3,
99
127.0, 126.7, 122,6, 118.3, 115.0, 117.5, 97.6, 47.7, 27.9. MS: m/z = 472.2 (M+1). Anal. calcd. for
3,4-dihydro-2H-chromen-2-amine (210h)
Yield 93 %, Off white solid, M.p. 134-136 oC, IR (KBr, νmax cm-1): 2996 (C-H), 1664 (C=N),
1419 (C=C), 1328 (C-F), 1276 (C-O). 1H NMR (300 MHz, DMSO-d6) δ (ppm): 2.52 (m, 1H, CH2), 3.2
(m, 1H, CH), 3.8 (m, 1H, CH), 3.84 (m, 1H, CH), 6.34 (m, 1H, Ar-H), 6.47 (m, 1H, Ar-H), 6.80 (t, 1H,
13
Ar-H, J = 7.2 Hz), 6.88-6.96 (m, 2H, Ar-H), 7.02-7.15 (m, 5H, Ar-H), 8.91 (s, 1H, CH). C NMR
(75 MHz, DMSO-d6) δ (ppm): 176.5, 173.8, 160.9, 159.7, 158.4, 155.6, 136.2, 135.0, 134.9, 133.7,
129.9, 128.1, 127.3, 126.8, 126.5, 122.6, 122.0, 121.5, 121.2, 117.1, 97.9, 47.5, 27.3. MS: m/z = 476
(M+1). Anal. calcd. for C24H15Br2F2N3O2: C, 50.11; H, 2.63; N, 7.3. Found: C, 50.17; H, 2.55; N, 7.28.
3.4.1.12. N-Benzylidene-3,4-dihydro-3-(5-phenyl-1,2,4-oxadiazol-3-yl)-2H-chromen-2-amine
(210i)
Yield 95 %, Off white solid, M.p. 140-142 oC, IR (KBr, νmax cm-1): 3000 (C-H), 1699 (C=N),
1
1284 (C-O). H NMR (300 MHz, DMSO-d6) δ (ppm): 2.59 (m, 2H, CH2), 3.2 (m, 1H, CH), 3.89 (m,
1H, CH), 6.31 (d, 1H, Ar-H, J = 8 Hz), 6.76-6.80 (m, 1H, Ar-H), 6.88 (d, 1H, Ar-H, J = 8 Hz), 6.96 (m,
1H, Ar-H), 7.03-7.14 (m, 5H, Ar-H), 7.15 (m, 2H, Ar-H), 7.34-7.39 (m, 1H, Ar-H), 7.58-7.61 (m, 2H,
13
Ar-H), 8.92 (s, 1H, CH). C NMR (75 MHz, DMSO-d6) δ (ppm): 176.2, 172.8, 150.9, 140.3, 132.8,
131.3, 131.0,130.6, 129.1, 127.1,126.0, 121.5,116.2, 98.0, 47.4, 27.2. MS: m/z = 382.2 (M+1). Anal.
calcd. for C24H19N3O2: C, 75.57; H, 5.02; N, 11.02. Found: C, 75.59; H, 5.02; N, 11.12.
3.4.1.13. 3,4-Dihydro-3-(5-(thiophen-2-yl)-1,2,4-oxadiazol-3-yl)-N-((thiophen-2-yl)methylene)-
2H-chromen-2-amine (210j)
100
Yield 73 %, Dark solid, M.p, 126-128 oC, IR (KBr, νmax cm-1): 2990 (C-H), 1675 (C=N),
1286(C-O). 1H NMR (300 MHz, DMSO-d6) δ (ppm): 2.58 (m, 2H, CH2), 2.89 (m, 1H, CH), 3.90 (m,
1H, CH), 6.82-6.86 (m, 1H, Ar-H), 6.96-6.98 (m, 1H, Ar-H,), 7.12-7.28 (m, 4H, Ar-H), 7.13-7.24 (m,
13
4H, Ar-H), 8.94 (s, 1H, CH). C NMR (75 MHz, DMSO-d6) δ (ppm): 171.2, 170.1, 153.9, 151.3,
132.8, 131.7, 131.3, 130.9, 129.8, 127.1, 126.0, 121.5, 116.2, 98.0, 47.2, 27.1. MS: m/z = 394.2 (M+1).
Anal. calcd. for C20H15N3O2S2: C, 61.05; H, 3.84; N, 10.68. Found: C, 61.25; H, 3.80; N, 10.69.
3.4.1.14. N-(4-Hydroxy-3-methoxybenzylidene)-3-(5-(4-hydroxy-3-methoxyphenyl)-1,2,4-
oxadiazol-3-yl)-3,4-dihydro-2H-chromen-2-amine (210k)
Yield 85 %, Off-White solid, M.p. 172-174 oC, IR (KBr, νmax cm-1): 2994 (C-H), 1660 (C=N),
1420 (C=C), 1328 (C-O). 1H NMR (300 MHz, DMSO-d6) δ (ppm): 2.48 (m, 1H, CH2), 2.96 (m, 1H,
CH), 3.88 (m, 1H, CH), 3.93 (s, 6H, -OCH3), 4.04 (m, 1H, CH), 6.65 (m, 1H, Ar-H), 6.77 (m, 2H, Ar-
H), 6.80-6.90 (m, 3H, Ar-H), 6.98-7.06 (m, 2H, Ar-H), 7.15-7.24 (m, 2H, Ar-H), 8.91 (s, 1H, CH), 9.6
(bs, 1H, -OH). 13C NMR (75 MHz, DMSO-d6) δ (ppm): 176.2, 173.2, 161.5, 156.1, 153.4, 149.7, 148.8,
129.4, 128.1, 126.0, 124.1, 123,2, 123.0, 120.5, 118.4, 117.8, 116.1, 115.5, 98.1, 47.9, 27.3. MS: m/z =
474.1 (M+1). Anal. calcd. for C26H23N3O6: C, 65.95; H, 4.90; N, 8.87. Found: C, 65.99; H, 4.80; N,
8.97.
3.4.1.15. N-(4-Bromobenzylidene)-3-(5-(4-bromophenyl)-1,2,4-oxadiazol-3-yl)-3,4-dihydro-2H-
chromen-2-amine (210l)
Yield 94 %, Off-White solid, M.p. 151-154 oC, IR (KBr, νmax cm-1): 3015 (C-H), 1689 (C=N),
1412 (C=C), 1290 (C-O). 1H NMR (300 MHz, DMSO-d6) δ (ppm): 2.56 (m, 2H, CH2), 3.32 (m, 1H,
CH), 3.97 (m, 1H, CH), 6.71 (m, 1H, Ar-H), 6.91 (d, 1H, Ar-H, J = 7.6 Hz), 7.0 (t, 1H, Ar-H, J = 7.6
Hz), 7.19 (d, 1H, Ar-H, J = 7.6 Hz), 7.47-7.50 (m, 4H, Ar-H), 7.8 (d, 2H, Ar-H, J = 8.4 Hz), 7.90 (d,
101
2H, Ar-H, J = 9.2 Hz), 8.93 (s, 1H, CH). 175.3,172.5, 166.2, 162.9, 161.3, 156.7, 136.8, 131.0, 130.1,
129.1, 128.4, 126.3, 122.5, 117.1, 116.0, 115.6, 97.5, 47.7, 27.6. MS: m/z = 540 (M+1), 542 (M+2).
Anal. calcd. for C24H17Br2N3O2: C, 53.46; H, 3.18; N, 7.79. Found: C, 53.41; H, 3.12; N, 7.84.
chromen-2-amine (210m)
Yield 70 %, Brown solid, M.p. 136-138 oC, IR (KBr, νmax cm-1): 2994 (C-H), 1680 (C=N),
1283(C-O). 1H NMR (300 MHz, DMSO-d6) δ (ppm): 2.56 (m, 2H, CH2), 3.15 (m, 1H, CH), 4.12 (m,
1H, CH), 6.61 (d, 1H, Ar-H, J = 8 Hz), 6.76-6.80 (m, 1H, Ar-H), 6.88 (d, 1H, Ar-H, J = 8 Hz), 6.96 (m,
13
1H, Ar-H), 7.34-7.42 (m, 2H, Ar-H), 8.24-8.16 (m, 2H, Ar-H), 9.2 (s, 1H, CH). C NMR (75 MHz,
DMSO-d6) (ppm): 173.2, 165.7, 158.9,157.6, 155.6, 143.8, 131.2, 127.4, 126.0, 121.5, 119.8, 115.5,
97.8, 47.6, 27.3. MS: m/z = 394.2 (M+1). Anal. Calcd. For C18H13N5O2S2: C, 54.67; H, 3.31; N, 17.71.
3-yl)-3,4-dihydro-2H-chromen-2-amine (210n)
Yield 91 %, Off-White solid, M.p. 158-161 oC, IR (KBr, νmax cm-1): 3010 (C-H), 1688 (C=N),
1289 (C-O). 1H NMR (300 MHz, DMSO-d6) δ (ppm): 2.59 (m, 2H, CH2), 3.2 (m, 1H, CH), 3.89 (m,
1H, CH), 6.31 (d, 1H, Ar-H, J = 8 Hz), 6.76-6.80 (m, 1H, Ar-H), 6.88 (d, 1H, Ar-H, J = 8 Hz), 6.96 (m,
1H, Ar-H), 7.03-7.14 (m, 5H, Ar-H), 7.15 (m, 3H, Ar-H), 7.34-7.39 (m, 4H, Ar-H), 7.58-7.61 (m, 4H,
13
Ar-H), 8.92 (s, 1H, CH). C NMR (75 MHz, DMSO-d6) δ (ppm): 172.0, 165.7, 158.1, 157.1, 156.1,
154.6, 143.2, 142.8, 138.9, 131.2, 128.5, 127.4, 126.0, 121.9, 121.5, 119.8, 117.2, 115.5, 97.8, 47.6,
27.3. MS: m/z = 602.2 (M+1). Anal. calcd. for C36H25F2N3O4: C, 71.87; H, 4.19; N, 6.98. Found: C,
102
3.4.2. Spectral Data
103
S
O N
N O S
210j
104
S
O N
N O S
210j
C20H15N3O2S2
Mol. Wt.: 393.48
105
HO
O N
HO
N
N O
210c
HO
O N
HO
N
N O
210c
106
HO
O N
HO
N
N O
210c
107
HO
O N
HO
N
N O
210c
C24H19N3O4
Mol. Wt.: 413.43
108
Fig. 3.33: LCMS of compound 210c
HO
O N
HO
N
N O
210c
109
Cl
O N
N Cl
N O
210b
110
Cl
O N
N Cl
N O
210b
111
Cl
O N
N Cl
N O
210b Mol. Wt.: 450.32
3.5. Conclusion
elemental analyses. All the newly synthesized compounds were screened for antibacterial activity by
MIC method. The structural activity relationship (SAR) and antimicrobial activity of all the compound
3.6. References
1. (a).Tiemann, F., Kruger, P. Chem. Ber., 1884, 17, 1685-1698. (b).Eloy, F., “Preparation of 1,2,4-
oxadiazoles by dipolar addition to aliphatic nitrile oxide” NASA TTF-F-16861. January 1976,
112
Unclassified. (c) Pace, A., Pierro, P. “The new era of 1,2,4-oxadiazoles” Org. Biomol. Chem.
2009, 7, 4337−4348.
2. Vu, C. B., Corpuz, E. G., Merry, T. J., Pradeepan, S. G., Bartlett, C., Bohacek, R. S., Botfield, M.
C., Eyermann, C. J., Lynch, B. A., MacNeil, I. A., Ram, M. K., Schravendijk, M. R., Violette, S.,
Sawyer, T. K. “Discovery of Potent and Selective SH2 Inhibitors of the Tyrosine Kinase ZAP-70”
3. Ankersen, M., Peschke, B., Hansen, B. S., Hansen, T. K. “Investigation of bioisosters of the
growth harmone secretagogue L-692,429” Bioorg. Med. Chem. Lett. 1997, 7, 1293-1298.
4. Orlek, B. S., Blaney, F. E., Brown, F., Clark, M. S. G., Hadley, M. S., Hatcher, J., Riley, G. J.,
oxadiazoles as ligands for the muscarinic receptor” J. Med. Chem. 1991, 34 (9), 2726-2735.
5. Ohmoto, K., Yamamoto, T., Horiuchi, T., Imanishi, H., Odagaki, Y., Kawabata, K., Sekioka, T.,
Hirota, Y., Matsuoka, S., Nakai, H., Toda, M., Cheronis, J. C., Spruce, L. W., Gyorkos, A.,
Wieczorek, M. “Design and synthesis of new orally active nonpeptidic inhibitors of human
6. Ono, M., Haratake, M., Saji, H., Nakayama, M. “Development of novel β-amyloid probes based
7. Ladbury, J. E., Klebe, G., Freire, E. “Adding calorimetric data to decision making in lead
8. Patani, G. A., LaVoie, E. J. “Bioisosterism: A rational approach in drug design” Chem. Rev. 1996,
96, 3147−3176.
9. James, N. D., Growcott, J. W. “Zibotentan” Drugs of the Fut. 2009, 34 (8), 624-633.
10. Jones, A. M., Helm, J. M. “Emerging treatments in cystic fibrosis” Drugs. 2009, 69, 1903-1910.
113
11. Summa, V., Petrocchi, A., Bonelli, F., Crescenzi, B., Donghi, M., Ferrara, M., Fiore, F., Gardelli,
C., Gonzalez Paz, O., Hazuda, D. J., Jones, P., Kinzel, O., Laufer, R., Monteagudo, E., Muraglia,
E., Nizi, E., Orvieto, F., Pace, P., Pescatore, G., Scarpelli, R., Stillmock, K., Witmer, M. V.,
inhibitor for the treatment of HIVAIDS infection” J. Med. Chem. 2008, 51, 5843-5855.
12. Lee, S. H., Seo, H. J., Jung, M. E., Park, J. H., Park, H. J., Yoo, J., un, H., Na, J., Kang, S. Y.,
cannabinoid-1 receptor antagonists for the treatment of obesity” J. Med. Chem. 2008, 51, 7216-
7233.
13. Unangst, P. C., Shrum, G. P., Connor, D. T., Dyer, R. D., Schrier, D. J. “Novel 1,2,4-oxadiazoles
35, 3691-3698.
14. Zhang, H.-Z., Kasibhatla, S., Kuemmerle, J., Kemnitzer, W., Ollis- Mason, K., Qiu, L., Crogan-
Grundy, C., Tseng, B., Drewe, J., Cai, S. X. “Discovery and structure-activity relationship of 3-
15. Cottrell, D. M., Capers, J., Salem, M. M., DeLuca-Fradley, K., Croft, S. L., Werbovetz, K. A.
16. Palazzo, G., Tavella, M., Strani, G., Silverstrini, B. “1,2,4-Oxadiazoles-IV. Synthesis and
114
17. Breuer, H. “Nitroheterocycles. 1. Nitrofuryl- substituted 3-amino-1,2,4- oxadiazoles and 5- amino-
18. Johan, B. H., Roy, F. G. “Hydroxylamine derivatives as potential antimalarial agents. 1,2,4-
19. Haugwitz, R. D., Martinez, A. J., Venslavsky, J., Angel, R. G., Maurer, B. V., Jacobs, G. A.,
Narayanan, V. L., Cruthers, L. R., Szanto, J. “Antiparasitic agents. Synthesis and Anthelminitic
20. Tully, W. R., Gardner, C. R., Gillespie, R. J., Westwood. R. “2-(O xadiazoly1)- and 2-
21. Nicolaides, D. N., Fylaktakidou, K. C., Litinas, K. E., Hadjipavlou-Litina, D. “Synthesis and
22. Leite, A. C. L., Vieira, R. F., De Faria, A. R., Wanderley, A. G., Afiatpour, P., Ximenes, E. C.
P. A., Srivastava, R. M., de Oliveira, C. F., Medeiros, M. V., Antunes, E., Brondani, D. J.
isosteres of Pyridine and Pyrazinecarboxylic Acids” J. Med. Chem. 2001, 44, 1560-1563.
24. Jager, C., Laggner, C., Mereiter, K., Holzer, W. “A ring fission/C-C bond cleavage reaction with
10417-10422.
115
25. Srivasta, R. M., Analice de, A. L., Osnir, S. V., Marcelo J. da, C. S., Maria, T. J. A .
26. Cottrell, D. M., Capers, J., Salem, M. M., DeLuca-Fradley, K., Croft, S. L., Werbovetz, K. A.
27. Wells, M. A. W., Henninger, T. C., Fraga-Spano, Boggs, S. A. C. M., Matheis, M., Ritchie, D. M.,
8 (IL-8) receptor antagonists” Bioorg. Med. Chem Lett. 2004, 14, 4307-4311.
28. Xu, J., Wei, L., Mathvink, R., He, J., Park, Y. J., He, H., Leiting, B., Lyons, K. A., Marsilio, F.,
Patel, R. A., Wu, J. K., Thornberry, N. A., Weber, A. E. “Discovery of potent and selective
phenylalanine based dipeptidyl peptidase IV inhibitors” Bioorg. Med. Chem. Lett. 2005, 15, 2533-
2536.
29. Sun, L. C., Weili, L., Paul, A. S., John, R. S., James, W. J., David, S. J. R., Michael, J. G., Mary,
E. M. “Design of novel, potent, and selective human β-tryptase inhibitors based on α-keto-[1,2,4]-
30. Boys, M. L., Schretzman, L. A., Chandrakumar, N. S., Tollefson, M. B., Mohler, S. B., Downs, V.
L., Penning, T. D., Russell, M. A., Wendt, J. A., Chen, B. B., Stenmark, H. G., Wu, H.,
Spangler, D. P., Clare, M., Desai, B. N., Khanna, I. K., Nguyen, M. N., Duffin, T., Engleman,
V. W., Finn, M. B., Freeman, S. K., Hanneke, M. L., Keene, J. L., Klover, J. A., Nickols, G. A.,
Nickols, M. A., Steininger, C. N., Westlin, M., Westlin, W., Norring, S. A. “Convergent, parallel
116
synthesis of a series of β-substituted 1,2,4-oxadiazole butanoic acids as potent and selective αvβ3
31. Koufaki, M., Kiziridi, C., Nikoloudaki, F., Alexis, M. N. “Design and synthesis of 1,2-dithiolane
derivatives and evaluation of their neuroprotective activity” Bioorg. Med. Chem. Lett. 2007, 17,
4223-4227.
32. Huhtiniemi, T., Suuronen, T., Rinne, V. M., C. Wittekindt, C., Lahtela-Kakkonen, M., Jarho, E.,
Wallen, E. A. A., Salminen, A., Poso, A., Leppanen, J. “Oxadiazole-carbonyl amino thioureas as
33. Koryakova, A. G., Ivanenkov, Y. A., Ryzhova, E. A., Bulanova, E. A., Karapetian, R. N., Mikitas,
O. V., Katrukha, E. A., Kazey, V. I., Okun, I., Kravchenko, D. V., Lavrovsky, Y. V., Korzinov,
34. Rakesh, D. S., Lee, R. B., Tangallapally, R. P. L., Lee, R. E. “Synthesis, optimization and
35. Chandrakantha, B., Shetty, P., Nambiyar, V., Isloor, N., Isloor, A. M. “Synthesis, characterization
and biological activity of some new 1,3,4-oxadiazole bearing 2-flouro-4-methoxy phenyl moiety”
36. Kiss, L. E., H Ferreira, H. S., Torrão, L., Bonifacio, L. M., Palma, P. N., Pa-Silva, P. S., an
117
37. Hencken, C. P., Jones-Brando, L., Bordón, C., Stohler, R., Mot,t B. T., Yolken, R., Posner, G. H.,
selective and potent inhibitors of Toxoplasma gondii” J. Med. Chem. 2010, 53, 3594-3601.
38. Demont, E. H., Andrews, B. I., Bit, R. A., Campbell, C. A., Cooke, J. W. B., Deeks, N., Desai, S.,
Dowel, S. J., Gaskin, G., Gray, J. R. J., Haynes, A., Holmes, D. S., Kumar, U., Morse, M. A.,
Osborne, G. J., Panchal, T., Patel, B., Perboni, A., Taylor, S., Watson, R.,Witherington, J., Willis,
R. “Discovery of new selective SIP1 receptor agonist efficacious at low oral dose and devoid of
39. Kumar, R., Kumar, A., Jain, S., Kaushik, D. “Synthesis, antibacterial evaluation and QSAR
40. Shultz, M. D., Kirby, C. A., Stams, T., Chin, D. N., Blank, J., Charlat, O., Cheng. H., Cheung, A.,
Cong, F., Feng, Y., Fortin, P. D., Hood, T., Tyagi, V., Xu, M., Zhang, B., Shao, W. “[1,2,4]
inhibit tankyrases 1 and 2 via novel adenosine pocket binding” J. Med. Chem. 2012, 55, 1127-
1136.
41. Jadhav, R. D., Kadam, K. S., Kandre, S., Guha, T., Reddy, M. M. K., Brahma, M. K., Deshmukh,
N J., Dixit, A., Doshi, L., Potdar, N., Enose, A. A., Vishwakarma, R. M., Sivaramakrishnan, H.,
Srinivasan, S., Nemmani, K. V. S., Gupte, A., Gangopadhyay, A. K., Sharma, R. “Synthesis and
biaryl ureas as DGAT1 inhibitors.” Eur. J. Med. Chem. 2012, 54, 324-342.
118
42. Evdokimov, N. M., Kireev, A.,Yakovenko, A. A., Yu, M., Antipin, Igor, V., Magedov, Kornienko,
Reaction of Malononitrile with Aldehydes and Thiols” J. Org. Chem. 2007, 72, 3443-3453.
43. Adib, M., Jahromi, A. H., Tavoosi, N., Mahdavi, M., Bijanzadeh, H. R. “Microwave-assisted
44. Augustine, J. K., Akabote, V, Hegde, S. G., Alagaswamy, P. “PTAS-ZnCL2: An efficient catalyst
for synthesis of 1,2,4-Oxadiazoles from amidoximes and organic nitriles” J. Org. Chem. 2009, 74,
5640-5640.
45. Kaboudin, B., Malekzadeh, L. “Organic reactions in water: an efficient method for the synthesis of
119